CSIMarket
 


Corvus Pharmaceuticals Inc   (CRVS)
Other Ticker:  
 

Cumulative Corvus Pharmaceuticals Inc 's Working Capital Ratio for Trailing Twelve Months Period

CRVS's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

CRVS Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth -36.11 % -47.78 % -22.63 % -10.52 % 10.94 %
Y / Y Current Assets Growth -35.97 % -35.45 % -35.62 % -44.77 % -38.77 %
Working Capital Ratio for Trailing Twelve Months Period 4.44 4.39 4.12 4.39 4.94
Total Ranking # 408 # 790 # 916 # 940 # 979
Seq. Current Liabilities Growth -5.89 % -7.11 % -5.21 % -22.9 % -23.08 %
Seq. Current Assets Growth -15.53 % -12.7 % 6.64 % -18.58 % -14.84 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Current Liabilities decreased faster than Corvus Pharmaceuticals Inc 's average Current Assets, this led to increase in in Corvus Pharmaceuticals Inc 's Working Capital Ratio for Trailing Twelve Months Period to 4.44, Working Capital Ratio for Trailing Twelve Months Period remained below Corvus Pharmaceuticals Inc average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 108 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Corvus Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about CRVS
Working Capital Ratio CRVS in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 109
Sector # 217
S&P 500 # 452


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
14.78 8.13 4.12
(Dec 31 2018)   (Jun 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Rapt Therapeutics Inc   12.15 
Kalvista Pharmaceuticals Inc   12.00 
Chimerix Inc   11.90 
Kinnate Biopharma Inc   11.87 
Adicet Bio Inc   11.84 
Amarin Corp Plcuk  11.83 
Pardes Biosciences Inc   11.83 
Inozyme Pharma Inc   11.79 
Aerovate Therapeutics Inc   11.76 
Dianthus Therapeutics Inc   11.62 
Caladrius Biosciences Inc   11.57 
Eledon Pharmaceuticals Inc   11.54 
Lianbio  11.53 
Cymabay Therapeutics Inc   11.51 
Roivant Sciences Ltd   11.49 
Milestone Pharmaceuticals inc   11.48 
Tff Pharmaceuticals Inc   11.40 
Erasca Inc   11.38 
Cerevel Therapeutics Holdings Inc   11.36 
Acasti Pharma Inc   11.32 
Prelude Therapeutics Inc  11.26 
Sage Therapeutics Inc   11.21 
Protagonist Therapeutics inc   11.20 
Sinovac Biotech Ltd  11.11 
Spruce Biosciences Inc   11.10 
Verrica Pharmaceuticals Inc   11.10 
Rocket Pharmaceuticals Inc   11.06 
Cormedix Inc   11.01 
Infinity Pharmaceuticals Inc   10.83 
Reneo Pharmaceuticals Inc   10.66 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com